Market Research Report
Epiomic Epidemiology Series: Mucopolysaccharidosis-III (MPS-III) Sanfilippo Syndrome Forecast in 23 Major Markets 2017-2027
|Published by||Black Swan Analysis||Product code||436070|
|Published||Content info||74 Pages
Delivery time: 1-2 business days
|Epiomic Epidemiology Series: Mucopolysaccharidosis-III (MPS-III) Sanfilippo Syndrome Forecast in 23 Major Markets 2017-2027|
|Published: February 1, 2017||Content info: 74 Pages||
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on MPS-III (Sanfilippo Syndrome) in 23 Major Markets
Mucopolysaccharidosis-III, also known as MPS-III or Sanfilippo syndrome, is part of the Mucopolysaccharidoses (MPS) disorders - a group of rare genetic disorders caused by deficiencies of lysosomal enzymes. These are in-born errors of metabolism, and are autosomal recessive genetic disorders.
There are 4 distinct sub-types of MPS-III (A, B, C & D), with patients ranging from mild to severe in terms of symptoms. Prevalence of the different subtypes varies markedly country to country.
This report provides the current prevalent population for MPS-III across 23 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China, Australia, Netherlands, Denmark, Sweden, Norway, Turkey, Greece, Portugal, Poland, Estonia, Russia, Czech Republic) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of MPS-III have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.